Ellence
(epirubicin hydrochloride)Phase 3Small molecule
PfizerEpirubicin is a chemotherapy drug used to treat various types of cancer, including breast cancer and other solid tumors, by damaging cancer cells' DNA to stop them from growing.[1] Ellence is currently being investigated across 2 indications[3], with its most advanced program in Phase 3.[1]
Ellence is one of 92 small molecule programs targeting Breast Cancer. It is currently in Phase 3.
2
Indications
84
Total Trials
6
Active Trials
91
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Ellence
PfizerPhase 3
Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer47 trials
Show 44 more trials
Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer
Unknown status·—·Phase 3·NCT00070278·800 enrolled
Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00017095·1,856 enrolled
Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer
Active, not recruiting·IIRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy·Phase 3·NCT00433420·2,000 enrolled
Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer
Unknown status·—·Phase 3·NCT00516425·1,000 enrolled
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer
Unknown status·—·Phase 3·NCT01093235·800 enrolled
Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer
Completed·—·Phase 2·NCT00253500·15 enrolled
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)
Unknown status·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 3·NCT01031030·800 enrolled
Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1·NCT00008034·15 enrolled
Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer
Unknown status·IIRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy·Phase 3·NCT00005581·1,000 enrolled
Soft Tissue Sarcoma3 trials
Metastatic Cancer2 trials
Pancreatic Cancer2 trials
24 more indications
Small Cell Lung Cancer2 trials
Lymphoma2 trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00005584·1,649 enrolled
Stomach Cancer2 trials
Esophageal Cancer2 trials
Germ Cell Tumor1 trial
Peritoneal Cancer1 trial
Hepatocellular Carcinoma1 trial
Safety and Efficacy1 trial
Bladder Cancer1 trial
Gastroesophageal Junction Cancer1 trial
Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer
Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT01123473·29 enrolled
Malignant Mesothelioma1 trial
Rhabdomyosarcoma1 trial
HIV infection1 trial
Metastatic Prostate Cancer1 trial
Adenocarcinoma1 trial
Gastroesophageal Junction1 trial
Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach
Completed·—·Phase 2·NCT00601705·61 enrolled
Malignant Solid Tumors1 trial
Locally Advanced1 trial
Liver Cancer1 trial
Epirubicin and Thalidomide in Treating Patients With Liver Cancer
Completed·—·Phase 2·NCT00058487·12 enrolled
Endometrial Cancer1 trial
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer
Completed·NNordic Society of Gynaecological Oncology - Clinical Trials Unit·Phase 3·NCT00005583·400 enrolled
Chronic Lymphocytic Leukemia1 trial
Breast Neoplasms1 trial
Regulatory
FDA Approval Timeline[4]
Sep 15, 1999
ELLENCE
NDA NDA050778
Sep 15, 2006
EPIRUBICIN HYDROCHLORIDE
NDA NDA050807
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for epirubicin hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]